Exhibit 99.1
Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023
Forward-Looking Statements This communication contains forward-looking statements
(including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and
other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as
assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as
“may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various
factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional
capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it
difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials
for PDS0101 and other Versamune® and Infectimune™ based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration
studies concerning PDS0101 and other Versamune® and Infectimune™ based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the
future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses,
presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the
Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any
collaboration studies; to aid in the development of the Versamune® platform; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors
that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s
annual, quarterly and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune® is a registered trademark, and Infectimune™ is a trademark of PDS Biotechnology
Corporation KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or
metastatic, HPV-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS0101 addresses large and growing market with significant unmet need Transformational data generated with PDS0101 and PDS0301 in multiple Phase 2
clinical studies Financial: Cash as of March 31, 2023 $65.2M cash runway into Q3 2024 with initiation of a registrational trial in 2023 Executive Summary: Positioned for Market Leadership Company Overview T cell activating platforms and
antibody conjugated immuno-cytokine platform to develop safer, more effective and longer lasting cancer immunotherapies 1 2 3 4
Experienced Management Team Historical success in development and
commercialization of leading pharmaceutical products Frank Bedu-Addo, PhD Chief Executive Officer Senior executive experience with management of strategy and execution at both large pharma and biotechs Notable drug development: Abelcet®
(Liposome Company/ Elan) PEG-Intron® (Schering-Plough/ Merck) Matthew Hill Chief Financial Officer 20 years of financial and operational leadership roles for life sciences companies Former Chief Financial Officer of several publicly traded
companies Lauren V. Wood, MD Chief Medical Officer 30 years of translational clinical research experience Former Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Gregory Conn,
PhD Chief Scientific Officer Co-founder 35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing
PDS Biotech Versamune® Overview Designed to address limitations of current
immunotherapy PLATFORM: Induces powerful, long-lasting anti-tumor response by promoting uptake of tumor-specific proteins by the immune system and activates a specific signaling pathway that promotes the production of active
tumor-infiltrating multifunctional CD8 killer and CD4 helper T cells Versamune® PDS0101 PDS0102 PDS0103 PDS0104 Product Candidates
Versamune® Mechanism of Action Comprised of cationic lipids (R-DOTAP)
co-administered with proprietary tumor antigens, delivered via subcutaneous injection Delivers antigen to CD4 and CD8 T cells. Activates the Type I Interferon pathway, leading to potent, multifunctional, antigen specific T cell
responses Human clinical trials confirm induction and accumulation of multifunctional T cells in the tumor, which correlated with elimination of circulating tumor DNA and clinical response (SITC 2022) Recruits T cells to lymph nodes Trains T
cells to target tumors Arms T cells to kill tumor cells 1 2 3 Injection Site Lymph Node Tumor Site
Versamune® Based Oncology Pipeline Partnerships with World Class Institutions in
Immuno-Oncology Reference: Data on file. PDS Biotech Funded Candidate/ Study Indication Combination PC P1 P2 P3 R Partner(s) Clinical (Lead) PDS0101 (HPV)/ VERSATILE-002 Recurrent or metastatic HPV16-positive head and neck
cancer Arm 1: ICI naïve Arm 2: ICI refractory KEYTRUDA® (standard of care) IIT Studies PDS0101 (HPV)/ IMMUNOCERV 1st-line treatment of locally advanced (IB3-IVA) cervical cancer Chemo-radiation (standard of care) PDS0101 (HPV)/ Mayo
Clinic Pre-metastatic HPV-positive oropharyngeal cancer (OPSCC) Arm 1: PDS0101 monotherapy Arm 2: PDS0101 + KEYTRUDA® KEYTRUDA® (standard of care) Preclinical Candidates PDS0102(TARP) TARP-positive AML, prostate and breast
cancers TBD PDS0103 (MUC1) MUC1-positive breast, colon, lung, ovarian and other cancers TBD PDS0104(TRP2) Melanoma TBD Partner Co-Funded Fast Track Designation
HPV16-Positive Head and Neck Squamous Cell Cancer (HNSCC) Disease Overview and
Market Size
HNSCC is a Devastating Group of Cancers Reference: Noseyaba et al. 2018. Cancer.
Suicide Risk Among Cancer Survivors: Head and Neck Versus Other Cancers https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01688-9 https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.html *Human Papillomavirus Oral and
PharyngealCancers Genotype of *HPV-Positive Oral and Pharyngeal Cancer Paranasalsinuses Nasopharynx Oropharynx Hypopharynx Larynx Pharynx Tongue Salivaryglands OralCavity NasalCavity
Targeted treatment option to address the growing population of HPV16-positive
HNSCC and improve outcomes Novel MOA that is clinically effective in a broader patient population and provides more durable responses. Safer and more effective treatments that may be used with or in place of current standard of care
Better tolerability and less toxic alternatives to chemotherapy Despite the Availability of Treatments, Significant Unmet Needs Remain in Recurrent or Metastatic HNSCC KEYTRUDA® KEYTRUDA® Plus Chemo Chemotherapy + EGFR
Inhibitor Objective Response Rate (ORR) 19% 36% 35% Progression Free Survival (PFS) 3.2 mos 5.0 mos 5.0 mos 12-Month Survival Rate 50% 55% 44% Median Overall Survival (OS) 12.3 mos 13.6 mos 10.3 mos Key
Toxicities Anemia Fatigue Weight loss Hypokalemia Additional to KEYTRUDA®: Neutropenia Mucosal inflammation Thrombocytopenia Stomatitis Neutropenia Anemia Thrombocytopenia Nausea/vomiting Hypokalemia Rash Fatigue Mucosal
inflammation Treatment Related Grade 3+ Toxicities 17% 72% 69% Oncologist2 – Stated Unmet Medical Needs in HNSCC Standard of Care for Recurrent or Metastatic HNSCC – Published Results*1 1KEYNOTE-048 Study 2Primary Market Research
2022 * No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
Est. HPV16Locally Advanced,Unresectable andMetastatic HPV16-positive HNSCC
Presents a Significant Market Opportunity Largely Attributed to the High Rate of Oral HPV Infections in Men Data sources: 1 PD-L1 negative and PD-L1 positive populations (> 9000 incidence PD-L1
Positive) https://seer.cancer.gov/statfacts/html/oralcav.html; https://www.cdc.gov/cancer/hpv/basic_info/hpv_oropharyngeal.htm; https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01688-9;
https://seer.cancer.gov/statistics-network/explorer/application.html?site=3&data_type=1&graph_type=4&compareBy=sex&chk_sex_1=1&race=1&age_range=1&advopt_precision=1&hdn_view=0;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002133/ ~18,300 ~34,000 ~38,100 ~54,400 Est. U.S. HPV Positive Oral and Pharyngeal Cancer Est. U.S. Oral and Pharyngeal Cancer Est. HPV16 Genotype $2-3B Market Opportunity in US1 HPV
cancer incidences continue to increase despite preventive HPV vaccine HPV vaccination is not expected to impact the rate of HPV-positive cancer incidence for decades Existing immunotherapies cost $150,000+ annually per patient1 No available
HPV specific therapy Initial commercial opportunity for PDS0101
PDS0101 for HPV16-Positive HNSCC
PDS0101: A Novel Investigational HPV-Targeted Immunotherapy PDS0101 is given by
subcutaneous injection and stimulates a potent targeted T cell attack against HPV-positive cancers Interim VERSATILE-002 data suggests PDS0101 generates clinically effective immune responses The combination of PDS0101 with KEYTRUDA® has
demonstrated a favorable safety profile to date PDS0101 with KEYTRUDA® demonstrates significant disease control by shrinking tumors, delaying disease progression and prolonging survival
VERSATILE-002 Phase 2 Clinical Trial Objective: To assess the combination of
PDS0101 and KEYTRUDA® in ICI naïve subjects with recurrent or metastatic HPV-positive HNSCC KEYTRUDA® (pembrolizumab) FDA Approved Standard of Care Partner Study Design Open-label, non-randomized, adaptive design study N=54 Enrollment
complete Key Entry Criteria for ICI Naïve Subjects Recurrent or metastatic HNSCC ≥18 years of age HPV16-Positive tumor Combined positive score (CPS) ≥1 Pembrolizumab 200mg IV Q3W up to 35 Cycles (2 years) PDS0101 1 mL subcutaneous
injection at Cycles 1, 2, 3, 4 and 12 Study Treatment Primary: Best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1 Key Secondary: Progression Free Survival (PFS) per RECIST
1.1 Overall Survival (OS) Safety and tolerability Endpoints Fast TrackDesignation
Demographics of the ITT (Safety) and mITT (Efficacy) Populations Demographics and
Baseline Characteristics Demographic or Baseline Characteristic ITT Population (N=48) mITT Population (N=34) Age, Median (Min, Max) 62.5 (45, 83) 63.5 (46, 83) Sex, n (%) Male Female 45 (93.8) 3 (6.3) 32 (94.1) 2 (5.9) Race,
n (%) American Indian or Alaska Native Asian Black or African American Pacific Islander White Multiple Other 0 1 (2.1) 1 (2.1) 0 45 (93.8) 0 1 (2.1) 0 0 0 0 33 (97.1) 0 1 (2.9) ECOG, n (%) 0 1 30 (62.5) 18
(37.5) 20 (58.8) 14 (41.2) CPS, n (%)* <1 1-19 ≥20 1 (2.1) 27 (56.3) 20 (41.7) 0 17 (50.0) 17 (50.0) Summary of Exposure Exposure ITT Population (N=48) PDS0101 doses, Median (Min, Max) 4.0 (1, 5) PDS0101 doses, n,
(%) ≥1 dose ≥2 doses ≥3 doses ≥4 doses 5 doses 46 (95.8) 40 (83.3) 36 (75.0) 27 (56.3) 11 (22.9) Pembrolizumab doses, Median (Min, Max) 5.0 (1, 29) Pembrolizumab doses, n (%) ≥1 dose ≥2 doses ≥3 doses ≥4 doses ≥5 doses ≥6
doses ≥7 doses ≥8 doses ≥9 doses ≥10 doses 48 (100) 40 (83.3) 36 (75.0) 28 (58.3) 27 (56.3) 23 (47.9) 20 (41.7) 16 (33.3) 15 (31.3) 13 (27.1) Duration of treatment (months), Median (Min, Max) 3.5 (0.0, 19.5)
To Date 70.6% of Patients have Achieved Disease Stabilization or Tumor
Shrinkage Confirmed best overall response was determined based on confirmed CR or confirmed PR per RECIST 1.1 per investigator assessment. One subject (NE) died prior to target lesion measurement and is included in the mITT population
denominator. Four subjects experienced unconfirmed tumor shrinkage and subsequently experienced progressive disease. 30%Shrinkage 14/34 (41.2%) Confirmed and Unconfirmed Objective Response 9/34 (26.5%) Confirmed Partial and Complete
Response 15/34 (44.1%) Stable Disease 9/34 (26.5%) Progressive Disease 1/34 (2.9%) Not Evaluable (not included in Waterfall plot) 23/34 (67.6%) Tumor Reduction
Compelling Durability of the Anti-Tumor Response Progressive Free Survival (PFS)
per Investigator Assessment (mITT Population) Number of Subjects at Risk (Events) CPI Naïve 34 (0) 33 (1) 32 (2) 27 (6) 25 (7) 16 (11) 14 (12) 12 (12) 12 (12) 10 (12) 9 (13) 8 (14) 6 (15) 4 (15) 4 (15) 3 (16) 1 (18) 1
(18) 1 (18) 0 (18) N Events Median (Months) 95% CI(Months) 34 18 10.4 (4.2, 15.3) PFS = 10.4 months Demonstrated median PFS of 10.4 months; published results of 2-3 months for approved immune checkpoint inhibitors* * No control or
comparative studies have been conducted between immune checkpoint inhibitors and PDS0101; Ferris R.L., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck; N Engl J Med 2016; 375:1856-1867; Burtness B et al., Pembrolizumab
alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomized, open-label phase 3 study; Lancet 2019;
394(10212):1915-1928https://www.opdivo.com/head-and-neck-cancerhttps://www.keytruda.com/head-and-neck-cancer/keytruda-clinical-trials/
Promising Survival Benefit Overall Survival (OS) (ITT Population) Number of
Subjects at Risk (Events) CPI Naïve 47 (0) 41 (1) 36 (1) 31 (1) 29 (1) 26 (1) 23 (2) 19 (2) 17 (2) 16 (2) 13 (3) 13 (3) 13 (3) 13 (3) 12 (3) 11 (3) 6 (4) 5 (4) 4 (4) 3 (4) 2 (4) 0 (4) N Events Median (Months) 95%
CI(Months) 48 4 NE (15.3, NE) 12-month OS rate = 87.1% Demonstrated 12-month OS rate of 87.1%; published results of 35-50% for approved immune checkpoint inhibitors* * No control or comparative studies have been conducted between
immune checkpoint inhibitors and PDS0101; Ferris R.L., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck; N Engl J Med 2016; 375:1856-1867; Burtness B et al., Pembrolizumab alone or with chemotherapy versus cetuximab with
chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 048): a randomized, open-label phase 3 study; Lancet 2019;
394(10212):1915-1928https://www.opdivo.com/head-and-neck-cancerhttps://www.keytruda.com/head-and-neck-cancer/keytruda-clinical-trials/
67.6% of Patients Experienced Tumor Shrinkage Overall response: CR=Complete
Response; PR=Partial Response; SD=Stable Disease; PD=Progressive Disease; NE=Not Evaluable. Overall response was based on investigator assessment per RECIST v1.1. Survival status: A=Alive; D=Deceased. Alive subjects were based on the last
contact date. Complete Response Partial Response Stable Disease Progressive Disease Demonstrated objective response rate of 41% (confirmed and unconfirmed) No control or comparative studies have been conducted between immune checkpoint
inhibitors and PDS0101
Several Patients Approaching Two Years of Survival Blue Dot: Timing of last scan
demonstrating PD; Red Bars – PD, Grey Bars – SD, Green Bars – PR, Black Bar – CR, Orange Bars – survival period through last known date alive Days on Treatment and Survival Grouped by Best Overall Response mITT Population (n=34) with at
least 1 scan No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
Data Suggests Prolonged Responses (Durability) and Patient Survival PDS0101 +
KEYTRUDA® Data – Median PFS and 12 Month OS *median OS not yet reached KEYNOTE-048: Burtness B et al. Lancet 2019;394:1915-28, Published results for reference only 21 10.4 months 3.2 months 5.0 months 55% 87.1% 50% Median Progression
Free Survival (Months) 12-Month OS (%)* ® ® ® ® ® ® No control or comparative studies have been conducted between immune checkpoint inhibitors and PDS0101
Tumor Reduction, ORR and OS Remain Consistent Comparison: ASCO 2022 & 2023
PDS0101 + KEYTRUDA® Clinical Results *9-Month OS in 2022; 12-Month OS in 2023 ASCO 2022 vs ASCO 2023 Data 87.1% 87.2% 67.6% 64.7% 26.5% 29.4% 41.2% 41.2%
The Addition of PDS0101 to KEYTRUDA® Does not Appear to Compound Toxicity
Preferred Term n (%) Any PSD0101-KEYTRUDA® TRAE 37 (77.1) Injection site pain 24 (50.0) Fatigue 18 (37.5) Injection site swelling 13 (27.1) Injection site erythema 8 (16.7) Headache 7 (14.6) Injection site discoloration 7
(14.6) Injection site warmth 7 (14.6) Injection site inflammation 6 (12.5) Diarrhea 5 (10.4) Injection site pruritus 5 (10.4) Pruritus 5 (10.4) Dyspnea 4 (8.3) Pain 4 (8.3) Alanine aminotransferase increased 3
(6.3) Arthralgia 3 (6.3) Aspartate aminotransferase increased 3 (6.3) Blood creatinine increased 3 (6.3) Blood thyroid stimulating hormone increased 3 (6.3) Cough 3 (6.3) Hypothyroidism 3 (6.3) Rash 3 (6.3) Weight decreased 3
(6.3) PSD0101-KEYTRUDA® TRAE by Grade Grade 1 13 (27.1) Grade 2 19 (39.6) Grade 3 4 (8.3) Grade 4 0 Grade 5 0 Only 4 subjects had Grade 3 PDS0101-KEYTRUDA® TRAEs: fatigue, injection site reaction, blood alkaline phosphatase
increased, hyperglycemia, colitis, and rash No subjects had Grade 4 or 5 TRAEs No subject came off studydue to toxicity PDS0101+KEYTRUDA® Treatment Related Adverse Events (TRAE) >5% (ITT Population)
VERSATILE-003 Phase 3 Study Design Worldwide Randomized, Controlled Clinical
Study Progression free survival (PFS) and overall survival (OS) Primary Endpoints For the treatment of recurrent or metastatic HPV16-positive HNSCC Targeted Indication Randomization 1:1 n~330 PDS0101 +KEYTRUDA® PDS0101 + KEYTRUDA®
PDS0101 + KEYTRUDA® KEYTRUDA® KEYTRUDA® KEYTRUDA® Planned Interim Analysis: PFS and OS Planned Interim Analysis: OS + Final PFS Final Analysis:OS
VERSATILE-003 Timeline to Registrational Trial Initiation Worldwide Randomized,
Controlled Clinical Study to Be Initiated Q4 2023 with an Overall Estimated 90–100 Sites PDS0101 + KEYTRUDA® in Recurrent or Metastatic HPV16-Positive HNSCC 2Q 2022 3Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 FDA Fast Track designation for
PDS0101 + KEYTRUDA® Successful EOP2 meeting with FDA Initiate PDS0101 tech-transfer, scale up at selected Phase 3 clinical/commercial manufacture Complete Phase 3 clinical manufacturing of PDS0101 Obtain visibility to potential OS and PFS
information for VERSATILE-002 trial needed to finalize VERSATILE-003 trial design Complete CMC-related activities for PDS0101 Obtain feedback from EU regulatory agencies on protocol File amended IND with FDA for registrational
trial Initiate site activation and related clinical operational activities (4- to 6-month process) InitiateVERSATILE-003 Phase 3 Trial VERSATILE-002 Phase 2 Trial Progressing
Expanding Evidence of Consistent and Durable PDS0101 Clinical Results Across
Multiple Phase 2 Trial Indications PDS0101 is an HPV16-targeted immunotherapy PDS0101 is providing strong proof of concept data for the Versamune® technology platform Efficacy data in >90 patients to date Strong agreement between
preclinical and clinical results Versamune® mechanism of action shows clear translation between preclinical and human results Anti-tumor responses and bio-marker data show strong correlation across all types of HPV-positive cancer and at all
stages of the disease Safety data in approximately 120 patients to date Safety data, anti-tumor responses and patient survival suggest that the Versamune® based therapies such as PDS0101 could be ideal candidates for combination oncology
treatments
Antibody-Conjugated IL-12 (PDS0301)
PDS Biotech Antibody-Conjugated IL-12 (PDS0301) Overview Antibody-Conjugated
IL-12 Opportunities Overcomes tumor’s ability to suppress attack by T cells. PDS0301 is a novel investigational tumor-targeting IL-12 that enhances the proliferation, potency and longevity of T cells in the tumor
microenvironment Monotherapy Combinations: Versamune® Based Immunotherapies Chemotherapy Radiation HDAC Inhibitors* *Histone Deacetylase Inhibitor
Antibody-Conjugated IL-12 (PDS0301) A novel investigational tumor-targeting
Interleukin 12 (IL-12) that enhances the proliferation, potency and longevity of T cells in the tumor microenvironment Together with Versamune® based immunotherapies PDS0301 works synergistically to promote a targeted T cell attack against
cancers PDS0301 is given by a simple subcutaneous injection Clinical data suggest the addition of PDS0301 to Versamune® based immunotherapies demonstrate disease control by shrinking tumors and prolonging survival in recurrent or metastatic
cancers with poor survival prognosis
Antibody-Conjugated IL-12: PDS0301 Targets Tumors and Enhances T Cell Infiltration
and Proliferation in the Tumor Tumor Site Injection Site Non-Immunogenic (Cold Tumor) Immunogenic (Hot Tumor) Tumor Site PDS0301 travels direct to tumor Increased tumor inflammation from PDS0301 PDS0301 increases T cell infiltration
and expansion in tumor CD8 T cells kill tumor cells 1 2 3 4
Antibody-Conjugated IL-12 (PDS0301) Regimens Reference: Data on file. Candidate/
Study Indication Combination PC P1 P2 P3 R Partner(s) IIT Studies PDS0301/ NCI-led Triple Combination HPV-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers Arm 1: ICI naive Arm 2: ICI refractory PDS0101
& ICI IIT Studies PDS0301 Advanced Kaposi Sarcoma Monotherapy PDS0301 Metastatic Castration sensitive and Castration Resistant Prostate Cancer Docetaxel PDS0301 Localized High and Intermediate Risk Prostate Cancer Radiation
Therapy PDS0301 ICI Refractory HPV-related, colon and small-bowel cancer HDAC Inhibitor Partner Co-Funded
NCI-led Triple Combination: PDS0301 + PDS0101 + ICI Advanced HPV16-Positive Anal,
Cervical, Head and Neck, Penile, Vaginal, Vulvar Cancer Patients Who Are ICI Refractory 173% grade 3 and higher adverse events reported in KEYNOTE-048 Burtness 2019 https://doi.org/10.1016/S0140-6736(19)32591-7 Goswami 2022
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0695 Partner FDA Approved Standard of Care None Immunology/Immune Correlates SITC, November 2022: Greater than two-fold increase in HPV16-specific T cells in the blood of 11/14 (79% ) of the
evaluated patients Induction of multifunctional killer (CD8) T cells Increases in granzyme B (associated with active killer T cells), IFN-γ, TNF-α, etc., signal a pro-inflammatory response and role in overcoming tumor immune suppression
Safety Safety results (Arms 1 & 2)1 24/50 (48%) of patients experienced grade 3 and higher adverse events 2/50 (4%) experienced grade 4 adverse events
Phase 2 Results in Recurrent Metastatic ICI Refractory HPV-Positive Cancer
(CPS>0; PD-L1 agnostic) Plot Includes Published Data in HSNCC NCI-led Triple Combination: PDS0301 + PDS0101 + ICI Advanced HPV16-positive ICI Refractory Cancer Patients *Published results for ICI monotherapy <10%, Strauss J, et al. J
Immunother Cancer 2020;8:e001395. doi:10.1136/jitc-2020-001395 N=29 Best published median OS data to date in ICI refractory head and neck cancer population is 8.2 months Objective Response (ORR) in High Dose PDS0301 Group = 63% (5/8)*
Infectimune™ Infectious Disease Platform
License agreement with University of Georgia for proprietary influenza
antigens Top-line preclinical data announced; effective delivery of flu proteins activate the critical immune signals necessary to generate neutralizing antibody responses to all flu strains tested in animals Preclinical data presented at the
41st Annual meeting of the American Society Virology Meeting Universal Flu Market Opportunity in 2021 PDS0202: Universal Prevention of Influenza PDS0202 Provided Full Protection Against Lethal Challenge with H1N1 Pandemic Strain in
Preclinical Study Reference: Ross T. and Woodward J. et al. evaluation of the PDS0202 (Infectimune™+ COBRA) Universal flu formulation. Proprietary Computationally Designed Influenza Protein % survival Day post infection Universal
Influenza Vaccines $7 Billion
Projected Milestones Through 3Q24 Trials are investigator-initiated trials and
data read-outs are outside the control of the Company 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 PDS0101 Anticipate updated data (VERSATILE-002) File amended IND with FDA for registrational trial for PDS0101 (VERSATILE-003) Completion of
enrollment (VERSATILE-002) Initiate registrational trial for PDS0101 (VERSATILE-003) Anticipate preliminary efficacy data from Mayo Clinic IIT Anticipate updated data (IMMUNOCERV) Final data VERSATILE-002 PDS0103 Estimated IND filing
inMUC1-related Cancers
PDS0101 to enter Phase 3 registrational trial in 2023 to treat recurrent or
metastatic, HPV-positive head and neck squamous cell cancer (HNSCC) Fast Track Designation PDS0101 addresses large and growing market with significant unmet need Transformational data generated with PDS0101 and PDS0301 in multiple Phase 2
clinical studies Financial: Cash as of March 31, 2023 $65.2M cash runway into Q3 2024 with initiation of a registrational trial in 2023 Executive Summary: Positioned for Market Leadership Company Overview T cell activating platforms and
antibody conjugated immuno-cytokine platform to develop safer, more effective and longer lasting cancer immunotherapies 1 2 3 4
Thank you